Early stage but promising: The recent... - Fight Prostate Ca...

Fight Prostate Cancer

2,956 members1,313 posts

Early stage but promising

Maxone73 profile image
7 Replies

The recent discovery of a selective MMP7 inhibitor represents a promising advancement in cancer treatment. MMP7, an enzyme involved in the breakdown of the extracellular matrix, is often overexpressed in aggressive cancers, including prostate cancer, facilitating tumor invasion and metastasis.

Very early stage, but consider that till not long ago, this enzyme was considered undruggable.

prostatewarriors.com/2024/1...

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...
7 Replies
NPfisherman profile image
NPfisherman

Maximus,

It is how we build on the knowledge. I have long been an advocate of combination therapy attack on PCa. Despite being a "cold tumor" providing challenges to the use of immunotherapy, the Science continues to find new targets to hit Mr PCa in the nutsack.

Someday, we may find a combo attack that finds a cure or stable disease status, like HIV has become for nearly all HIV patients..

The Science is Coming !!! and it ROCKS !!!

Don Pescado

Maxone73 profile image
Maxone73 in reply toNPfisherman

It damn sure rocks!!!

NPfisherman profile image
NPfisherman in reply toMaxone73

You're darn "skippy" it does.... The Science is getting there....not always as fast as we like.. but progress is made daily !!!

TC007 profile image
TC007 in reply toNPfisherman

Only question is - will that Science be affordable for those who are not millionaires? Probably Not! The divide between cancer treatment between rich and poor is increasing rapidly. For general public Chemo will stay first line of treatment for long time.

Maxone73 profile image
Maxone73 in reply toTC007

Yes and no. Usually competition creates lower prices, nowadays it's not like 20-30 years ago where pharma was big pharma only (10 companies in the world?). There are thousands of smaller pharma companies now that with a good intuition and a lower amount of money (AlphaFold is open source now for example) can create solutions. Also repurposing is moving forward. I had a financial report in my hands few days ago, only for prostate cancer (all stages) there are 150 companies testing 166 products clinically.

If you ask me (notorious "wannabe-hippie-peace-love") if for one year the countries that spend the most in weapons decided to spend 50% of that budget on research, in 2-3 year we would probably be cancer free and the cost of those drugs would be lower. But that's just my opinion!

Anyway, at the moment you are right in the sense that between the north and the south of the world there is a huge gap in access, and that should be addressed.

TC007 profile image
TC007 in reply toMaxone73

I agree with you and my biggest hope is from repurpuposed drugs and AI discovering it. Regarding smaller pharma companies- Big Pharma is not in the business of creating new solutions. Their major job is to acquire high potential smaller companies. Once a smaller company moves to phase 3 then most of the times you will hear that it received acquisition offer. Big pharma lobby is now more powerful than 30 Years back

Maxone73 profile image
Maxone73 in reply toTC007

Yes, but they buy them to carry on the research. We have way more power to hurt big pharma in case they delay a promising drug to make more money with the ones already in use. And also big pharma is not 10 companies anymore.

Not what you're looking for?

You may also like...

Monoamine oxidase A (MAOA): A promising target for prostate cancer therapy

New paper below [1]. {MAOA has been a promising therapy for 20 years imo.} "Previous studies have...
pjoshea13 profile image

The Role of HSD3B1 in Prostate Cancer Progression and Treatment

I don't think I was tested against this gene, so I think it could be important for me as well. A...
Maxone73 profile image

Docosahexaenoic acid enhances the treatment efficacy for CRPCa by inhibiting autophagy through Atg4B inhibition, 2024 Aug 23

Possible simple dietary intervention to increase autophagy in PCa and boost efficacy of ARSIs....
cujoe profile image

Early (but not too early) PSA drop is a predictor of ADT efficacy (+ apalutamide)

Early PSA response at 6 months is both a predictor and a causal mediator of treatment efficacy for...
Maxone73 profile image

This protocol works for me

After thirteen months, my NAGALASE count .95 is in the high normal range and my final weekly Vit...
agnut profile image